Healios K.K. ( heal Japan, Inc.) is a Japanese biotechnology company headquartered in Tokyo, Japan, focused on developing innovative regenerative medicine therapies using induced pluripotent stem cell (iPSC) technology [1](https://www.healios.co.jp/en/). The company is a pioneer in the Japanese iPSC research ecosystem and aims to deliver "cures and hope to patients with unmet medical needs" [2](https://www.healios.co.jp/en/).
Company Background
Founded: 2011
Headquarters: Tokyo, Japan
Stock Exchange: TSE Mothers (4596)
Focus: iPSC and somatic stem cell-based regenerative medicine
Focus Areas
Healios develops regenerative medicine products in two primary areas:
Focus on age-related diseases with high unmet medical needs
Somatic Stem Cell Therapies
Using adult stem cells for tissue repair
Acute care applications
Trauma and critical illness treatment
Pipeline Products
Neurological Disorders
Ischemic Stroke
Healios is developing a somatic stem cell therapy for acute ischemic stroke, one of the leading causes of death and disability worldwide. This program aims to improve functional recovery in stroke patients through regenerative mechanisms.
Other Pipeline Programs
...
Overview
Healios K.K. ( heal Japan, Inc.) is a Japanese biotechnology company headquartered in Tokyo, Japan, focused on developing innovative regenerative medicine therapies using induced pluripotent stem cell (iPSC) technology [1](https://www.healios.co.jp/en/). The company is a pioneer in the Japanese iPSC research ecosystem and aims to deliver "cures and hope to patients with unmet medical needs" [2](https://www.healios.co.jp/en/).
Company Background
Founded: 2011
Headquarters: Tokyo, Japan
Stock Exchange: TSE Mothers (4596)
Focus: iPSC and somatic stem cell-based regenerative medicine
Focus Areas
Healios develops regenerative medicine products in two primary areas:
Healios is developing a somatic stem cell therapy for acute ischemic stroke, one of the leading causes of death and disability worldwide. This program aims to improve functional recovery in stroke patients through regenerative mechanisms.
Healios utilizes iPSC technology to develop regenerative medicine therapies:
Cell Derivation: Generating pluripotent stem cells from patient or donor cells
Differentiation: Directing stem cells to become specific cell types needed for therapy
Quality Control: Rigorous testing to ensure safety and efficacy
Allogeneic Approach: Developing off-the-shelf products usable across patients
Manufacturing Platform
Healios has established a robust manufacturing platform for iPSC-based products:
State-of-the-art cell culture facilities
Scalable production methods
Stringent quality control standards
Compliance with Japanese regenerative medicine regulations
neurodegeneration" style="color:#4fc3f7;margin:1.5rem 0 0.6rem;font-size:1.15rem;font-weight:700;border-bottom:2px solid rgba(79,195,247,0.3);padding-bottom:0.3rem">Relevance to Neurodegeneration
While Healios' current primary focus is not directly on Alzheimer's or Parkinson's disease, their platform has significant relevance to neurodegeneration:
iPSC Technology: iPSC-derived [neurons](/entities/neurons) can be used to model neurodegenerative diseases and screen potential therapeutics
Stroke Program: Ischemic stroke shares common pathways with vascular dementia
Regenerative Capacity: The platform technology can potentially be adapted for neurodegenerative conditions
Neural Cell Therapy: Experience in neural differentiation could lead to future Parkinson's or Alzheimer's therapies
Disease Modeling: iPSC technology enables patient-specific disease modeling for research
Leadership
Healios is led by experienced executives with backgrounds in:
[Pharmaceutical](/companies) development
iPSC research
Cell therapy manufacturing
Clinical development
Partnerships and Collaborations
Healios maintains collaborations with:
Academic research institutions
University hospitals for clinical trials
[Pharmaceutical](/companies) partners for co-development
Regulatory Status
Healios operates under Japan's regenerative medicine framework, including:
[Pharmaceutical](/companies) and Medical Device Act (PMD Act)
Regenerative Medicine Promotion Act
Conditional approval pathway for regenerative medicine products